Global Molecular Transplant Diagnostics Market to Triple Revenue
By LabMedica International staff writers Posted on 09 May 2017 |
Image: The global market for molecular transplant diagnostics is projected to grow at an average annual rate of 9% up to 2021 (Photo courtesy of Kalorama Information).
The global market for molecular transplant diagnostics is estimated to be over USD 300 million and is projected to grow at an average annual rate of 9% up to 2021. These are the latest findings of Kalorama Information, an independent medical market research firm.
Molecular testing technologies are well suited for solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants, which require histocompatibility between the recipient and donor for successful outcomes. The various PCR-based methodologies, Sanger sequencing and NGS used to type HLA alleles in low to high resolution in order to match donors and recipients for solid organ and HSCT or bone marrow transplants; post-transplant monitoring including for transplant rejection is an ancillary testing area. Allogenic HSCT transplantation is a comparatively high growth procedure area in comparison to solid organ transplantation and is a leading area of application for molecular HLA typing.
Over allogenic 9,000 HSCTs and approximately 30,000 solid organ transplants are performed in the US each year, making it the world’s largest market for molecular transplant diagnostics. The large size of the US molecular transplant diagnostics market is sustained by the demand for high resolution molecular HLA typing, including sequencing-based methods. In Europe, over 30,000 solid organ transplants and around 18,000 HSCTs are performed each year with transplant volumes in the region continuing to grow at a faster pace as compared to the US. This is due to the higher number of solid organ transplants and HSCTs being performed in the Eastern European countries and other less mature markets, thereby driving sales of test products.
"Molecular is not ubiquitous, as some forecasters – including us- may have thought a decade ago," said Bruce Carlson, Publisher of Kalorama Information. "It performs well in areas where it is set apart from other technologies. HLA is a value-add area for molecular, and you see that in the growth rate."
Molecular testing technologies are well suited for solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants, which require histocompatibility between the recipient and donor for successful outcomes. The various PCR-based methodologies, Sanger sequencing and NGS used to type HLA alleles in low to high resolution in order to match donors and recipients for solid organ and HSCT or bone marrow transplants; post-transplant monitoring including for transplant rejection is an ancillary testing area. Allogenic HSCT transplantation is a comparatively high growth procedure area in comparison to solid organ transplantation and is a leading area of application for molecular HLA typing.
Over allogenic 9,000 HSCTs and approximately 30,000 solid organ transplants are performed in the US each year, making it the world’s largest market for molecular transplant diagnostics. The large size of the US molecular transplant diagnostics market is sustained by the demand for high resolution molecular HLA typing, including sequencing-based methods. In Europe, over 30,000 solid organ transplants and around 18,000 HSCTs are performed each year with transplant volumes in the region continuing to grow at a faster pace as compared to the US. This is due to the higher number of solid organ transplants and HSCTs being performed in the Eastern European countries and other less mature markets, thereby driving sales of test products.
"Molecular is not ubiquitous, as some forecasters – including us- may have thought a decade ago," said Bruce Carlson, Publisher of Kalorama Information. "It performs well in areas where it is set apart from other technologies. HLA is a value-add area for molecular, and you see that in the growth rate."
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus